Live Breaking News & Updates on Saraj Tai

Stay updated with breaking news from Saraj tai. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Deconstructing Health Inequity - A Perceptual Control Theory Perspective | Timothy A. Carey


Deconstructing Health Inequity
Authors:
Draws on experience from cross-cultural settings; rural, remote, and underserved communities; community mental health settings; prisons; schools; and psychiatric wards
Provides fresh insight for academics, practitioners, and policymakers in the fields of public health, psychology, social policy, and healthcare
Buy this book
Hardcover
$69.99
price for USA
Customers within the U.S. and Canada please contact Customer Service at +1-800-777-4643, Latin America please contact us at +1-212-460-1500 (24 hours a day, 7 days a week). Pre-ordered printed titles are excluded from promotions.
Due: May 6, 2021
Institutional customers should get in touch with their account manager
This book offers a radically different perspective on the topic of health inequity. Carey, Tai, and Griffiths use Perceptual Control Theory (PCT) to deconstruct c ....

Greater Manchester , United Kingdom General , United Kingdom , Andrew Weiss , Saraj Tai , Timothya Carey , University Of Global Health Equity , Institute Of Global Health Equity Research , Global Health , University Of Manchester , Greater Manchester Mental Health , Global Health Equity Research , Andrew Weiss Chair , Global Health Equity , Senior Lecturer , Clinical Psychology , Consultant Clinical Psychologist , Clinical Research Fellow , Mental Health Nursing , Mental Health Nursing Research Unit , Research Fellow , Perceptual Control , அதிகமானது மான்செஸ்டர் , ஒன்றுபட்டது கிஂக்டம் ஜநரல் , ஒன்றுபட்டது கிஂக்டம் , ஆண்ட்ரூ வெயிஸ் ,

COMPASS Pathways announces publication in Frontiers in Psychiatry of paper on therapist training programme for psilocybin therapy


COMPASS Pathways announces publication in Frontiers in Psychiatry of paper on therapist training programme for psilocybin therapy
COMPASS Pathways announces publication in of paper on therapist training programme for psilocybin therapy Formal and scalable methodology for psychological support in psilocybin therapy London, UK 3 February 2021 COMPASS Pathways plc a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, has shared details of its comprehensive and rigorous therapist …
COMPASS Pathways announces publication in
Frontiers in Psychiatry
Formal and scalable methodology for psychological support in psilocybin therapy
London, UK 3 February 2021
COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, has shared details of its comprehensive and rigorous therapist training p ....

New York , United States , United Kingdom , Eteläuomen Läi , City Of , Ekaterina Malievskaia , Peter Gasser , Tracy Cheung , Stephen Schultz , Williama Richards , School Of Medicine , Saraj Tai University Of Manchester , Drug Administration , Exchange Commission , Riikka Ajantaival Clinical Research Institute , Bayview Medical Center , Helsinki University Central Hospital , Psychiatric Institute , Aquilino Cancer Center , Frederick Reinholdt King College London , New Drug , Johns Hopkins Bayview Medical Center , Elizabeth Nielson , Riikka Ajantaival , Clinical Research Institute , Saraj Tai ,

Compass Pathways: COMPASS Pathways announces publication in Frontiers in Psychiatry of paper on therapist training programme for psilocybin therapy


Compass Pathways: COMPASS Pathways announces publication in Frontiers in Psychiatry of paper on therapist training programme for psilocybin therapy
Frontiers in Psychiatry
Formal and scalable methodology for psychological support in psilocybin therapy
London, UK - 3 February 2021
COMPASS Pathways plc today. The programme sets out a formal and scalable methodology for psychological support in psilocybin therapy. It is currently being used to train therapists taking part in COMPASS s phase IIb clinical trial of COMP360 psilocybin therapy for treatment-resistant depression, as approved by the US Food and Drug Administration (FDA), as part of COMPASS s Investigational New Drug (IND) application.
In psilocybin therapy, patients are given a dose of psilocybin, a psychedelic substance, in conjunction with psychological support from specially trained therapists. COMPASS developed the therapist training programme alongside leading experts in mental health and psychedel ....

Eteläuomen Läi , United Kingdom , City Of , Ekaterina Malievskaia , Peter Gasser , Tracy Cheung , Stephen Schultz , Williama Richards , School Of Medicine , Saraj Tai University Of Manchester , Drug Administration , Exchange Commission , Riikka Ajantaival Clinical Research Institute , Bayview Medical Center , Helsinki University Central Hospital , Psychiatric Institute , Aquilino Cancer Center , Frederick Reinholdt King College London , New Drug , Johns Hopkins Bayview Medical Center , Elizabeth Nielson , Riikka Ajantaival , Clinical Research Institute , Saraj Tai , Briand Richards , Enoch Pratt Hospital ,